Call us: + 31 (0)20 - 4350 580

Home > Case studies > From CDP to phase I/II study in GBM, to success...

From CDP to phase I/II study in GBM, to successful out-license deal

From CDP to phase I/II study in GBM, to successful out-license deal

A private biotech company in the Netherlands required assistance to realize their ambition to turn their targeted brain delivery technology platform into a medicinal product. As a first assignment, SMS-oncology prepared a (pre)clinical development plan outlining the strategy to obtain Proof of Concept with their lead compound for the treatment of brain metastases and primary brain cancers. Subsequently, SMS-oncology developed the protocol for the Phase I/IIa study, which has been successfully executed by SMS-oncology in patients with glioblastoma multiforme or brain metastasis from solid tumors, in 10 sites throughout the Netherlands, Belgium, France and the US. Following the writing of the CSR by SMS-oncology, the Dutch biotech entered into an exclusive global license agreement for their liposomal chemotherapy